- Home
- CPBI vs PRLD Comparison
CPBI vs PRLD Comparison
Compare CPBI & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | PRLD |
|---|---|---|
| Founded | 2023 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 69.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CPBI | PRLD |
|---|---|---|
| Price | $17.51 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 3.3K | ★ 547.0K |
| Earning Date | 02-10-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.32 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $19,961,000.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.22 | ★ N/A |
| Revenue Growth | 9.30 | ★ 250.00 |
| 52 Week Low | $13.00 | $0.61 |
| 52 Week High | $17.70 | $4.22 |
Technical Indicators
Market Signals| Indicator | CPBI | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 60.40 | 46.04 |
| Support Level | $16.86 | $1.90 |
| Resistance Level | $17.70 | $2.20 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 77.38 | 18.37 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.